FOAMIX PHARMACEUTICALS


Oppenheimer Initiates Outperform On Foamix Pharmaceuticals; Sees 163% Upside

In a research report issued today, Oppenheimer analyst Akiva Felt initiated coverage with an Outperform rating on Foamix Pharmaceuticals (NASDAQ:FOMX) and a $15 price target, which represents …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts